Epidemiology and pathogenesis of scleroderma

Australasian Journal of Dermatology

Volumn 44, Issue 1, 2003, Pages 1-7

  Chen, Keng ^a,b   See, Adrian ^a   Shumack, Stephen ^a  

^a ST GEORGE HOSPITAL   (Australia)

^b St George Dermatology and Skin Cancer Centre   (Australia)

Author keywords

Connective tissue; Environment; Fibrosis; Genetics; Immune system; Localized scleroderma; Microchimerism; Morphoea; Systemic sclerosis

Indexed keywords

CLINICAL FEATURE; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; EXTRACELLULAR MATRIX; GENETIC SUSCEPTIBILITY; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNOPATHOGENESIS; MICROCHIMERISM; OCCUPATIONAL HAZARD; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SCLERODERMA; SEX RATIO; VASCULAR ENDOTHELIUM; VASOSPASM;

EID: 0037328401     PISSN: 00048380     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-0960.2003.06301.x     Document Type: Review

References (80)

1. Tu JH, Eisen AZ, Scleroderma. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB (eds). Fitzpatrick's Dermatology in General Medicine, Vol. 2, 5th edn. New York: McGraw-Hill, 1999; 2023-33.
2. Peterson LS, Nelson AM, Su WPD, Mason T, O'Fallon WM, Gabriel SE. The epidemiology of morphoea (localised scleroderma) in Olmsted County 1960-1993. J. Rheum. 1997; 24: 73-80.
3. Roberts-Thomson PJ, Jones M, Hakendorf P, Kencana Dharmapatni AA, Walker JG, MacFarlane JG, Smith MD, Ahern MJ. Scleroderma in South Australia: Epidemiological observations of possible pathogenic significance. Intern. Med. J. 2001; 31: 220-9.
4. Mayes MD, Laing TJ, Gillespie BW, Cooper BC, Lacey JV, Hirschenberger WS, Atty SM, Schottenfeld D. Prevalence, incidence and survival rates of systemic sclerosis in the Detroit metropolitan area (Abstract). Arthritis Rheum. 1996; 39 (Suppl.): S150.
5. Silman A, Jannini S, Symmons D, Bacon P. An epidemiologic study of scleroderma in the West Midlands. Br. J. Rheumatol. 1988; 27: 286-90.
6. Tamaki T, Mori S, Takehara K. Epidemiologic study of patients with systemic sclerosis in Tokyo. Arch. Dermatol. Res. 1991; 283: 366-71.
7. Medsger TA Jr, Masi AT. Epidemiology of systemic sclerosis (scleroderma). Ann. Intern. Med. 1971; 74: 714-19.
8. McNeilage LI, Youngchaiyud U, Whittingham S. Racial differences in antinuclear antibody patterns and clinical manifestations of Scleroderma. Arthritis Rheum. 1989; 32: 54-60.
9. Reveille JD, Fischbach M, McNearney T, Friedman AW, Aguilar MB, Lisse J, Fritzler MJ, Ahn C, Arnett FC; GENISOS Study Group. Systemic sclerosis in 3 US ethnic study groups: A comparison of clinical, sociodemographic, serologic and immunologic determinants. Semin. Arthritis Rheum. 2001; 30: 332-46.
10. Tan FK, Arnett FC, Reveille JD, Ahn C, Antohi S, Sasaki T, Nishioka K, Bona CA. Autoantibodies to fibrillin 1 in systemic sclerosis: Ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles. Arthritis Rheum. 2000; 43: 2464-71.
11. Whyte J, Artlett C, Harvey G, Stephens CO, Welsh K, Black C, Maddison PJ, McHugh NJ. HLA-DQB1 associations with antitopoisomerase 1 antibodies in patients with systemic sclerosis and their first degree relatives. United Kingdom Systemic Sclerosis Study Group. J. Autoimmun. 1994; 7: 509-20.
12. Morel PA, Chang H J, Wilson JW, Conte C, Falkner D, Tweardy DJ, Medsger TA Jr. HLA and ethnic associations among systemic sclerosis patients with anticentromerc antibodies. Hum. Immunol. 1995; 42: 35-42.
13. Gilchrist FC, Bunn C, Foley PJ, Lympany PA, Black CM, Welsh KI, du Bois RM. Class II HLA associations with autoantibodies in scleroderma: A highly significant role for HLA-DP. Genes Immun. 2001; 2: 76-81.
14. De Keyser F, Peene I, Joos R, Naeyaert JM, Messiaen L, Veys EM. Occurrence of scleroderma in monozygotic twins. J. Rheumatol. 2000; 27: 2267-9.
15. Arnett FC, Cho M, Chatterjee S, Aguilar MB, Reveille JD, Mayes MD. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in 3 United States cohorts. Arthritis Rheum. 2001; 44: 1359-62.
16. Maddison PJ, Skinner RP, Pereira RS, Black CM, Ansell BM, Jayson MI, Rowel NR, Welsh KI. Antinuclear antibodies in the relatives and spouses of patients with systemic sclerosis. Ann. Rheum. Dis. 1986; 45: 793-9.
17. Silman AJ, Hochberg MC. Occupational and environmental influences on scleroderma. Rheum. Dis. Clin. North Am. 1996; 4: 737-47.
18. Haustein UF, Hermann K. Environmental scleroderma. Clin. Dermatol. 1994; 12: 467-73.
19. Haustein UF, Anderegg U. Silica induced scleroderma: Clinical and experimental aspects. J. Rheumatol. 1998; 25: 1917-26.
20. Englert H, Small-McMahon J, Davis K, O'Connor H, Chambers P, Brooks P. Male systemic sclerosis and occupational silica exposure - a population based study. Aust. NZ. J. Med. 2000; 30: 215-20.
21. Steen VD. Occupational scleroderma. Curr. Opin. Rheum. 1999; 11: 490-4.
22. Whorton D, Wong O. Scleroderma and silicone breast implants. West. J. Med. 1997; 167: 159-65.
23. Weide B, Walz T, Garbe C. Is morphoea caused by Borrelia burgdorferi? A review. Br. J. Dermatol. 2000; 142: 636-44.
24. Prescott RJ, Freemont AJ, Jones CJP, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J. Pathol. 1992; 166: 255-65.
25. Herron GS, Romero LI. Vascular abnormalities in scleroderma. Semin. Cutan. Med. Surg. 1998; 17: 12-17.
26. Sgone R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependant cell-mediated cytotoxicity via CD95. Arthritis Rheum. 2000; 43: 2550-62.
27. Wetzig T, Petri JB, Mittag M, Haustein UF. Serum levels of soluble Fas/APO-1 receptor are increased in systemic sclerosis. Arch. Dermatol. Res. 1998; 200: 187-90.
28. LeRoy EC. Systemic sclerosis: A vascular perspective. Rheum. Dis. Clin. North Am. 1996; 22: 675-94.
29. Belch J. Raynaud's phenomenon: Its relevance to scleroderma. Ann. Rheum. Dis. 1991; 50: 839-45.
30. Coffman JD. Raynaud's phenomenon. J. Vasc. Med. Biol. 1994; 5: 259-69.
31. LeRoy EC, Medsger TA. Raynaud's phenomenon: A proposal for classification. Clin. Exp. Rheum. 1992; 10: 485-8.
32. Yamane K, Kashiwagi H, Suzuki N, Miyauchi T, Yanagisawa M, Goto K, Masaki T. Elevated plasma levels of endothelin-1 in systemic sclerosis. Arthritis Rheum. 1991; 34: 243-4.
33. Flavahan NA, Flavahan S, Liu Q, Tidmore W, Wiener CM, Spence RJ, Wigley FM. Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum. 2000; 43: 1886-90.
34. Murrell DF. A radical proposal for the pathogenesis of scleroderma. J. Am. Acad. Dermatol. 1993; 28: 78-85.
35. Maxwell S, Lip G. Reperfusion injury: A review of the pathophysiology, clinical manifestations and therapeutic options. Int. J. Cardiol. 1997; 58: 95-117.
36. Casiola-Rosen L, Wigley F, Rosen A. Scleroderma autoantigens are uniquely fragmented by metal catalysed oxidation reactions: Implications for pathogenesis. J. Exp. Med. 1997; 185: 71-9.
37. Leroy EC. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: A possible defect in the regulation or activation of the scleroderma fibroblast. J. Clin. Invest. 1974; 54: 880-9.
38. Lovell C, Nicholls A, Duance V, Bailey AJ. Characterisation of dermal collagen in systemic sclerosis. Br. J. Dermatol. 1979; 100: 359-69.
39. Buckinghan RB, Prince BK, Rodnan GP, Taylor F. Increased collagen accumulation in dermal fibroblast cultures from patients with progressive systemic sclerosis (scleroderma). J. Lab. Clin. Med. 1978; 92: 5-21.
40. Fleischmajer B, Perlish JS, Krieg T, Timpl R. Variability in collagen and fibronectin synthesis by scleroderma fibroblasts in primary culture. J. Invest. Dermatol. 1981; 76: 400-3.
41. Brady AH. Collagenase in scleroderma. J. Clin. Invest. 1975; 56: 1175-80.
42. Takeda K, Hatamochi A, Ueki H, Nakata M, Oishi Y. Decreased collagenase expression in cultures systemic sclerosis fibroblasts. J. Invest. Dermatol. 1994; 103: 359-63.
43. Wallis DD, Tan FK, Kielty CM, Kimball MD, Arnett FC, Milewicz DM. Abnormalities in fibrillin 1-containing microfibrils in dermal fibroblasts cultures from patients with systemic sclerosis (scleroderma). Arthritis Rheum. 2001; 44: 1855-64.
44. Sapadin AN, Esser AC, Fleischmajer R. Immunopathogenesis of scleroderma - evolving concepts. Mt Sinai J. Med. 2001; 68: 253-42.
45. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J. Rheumatol. 1997; 24: 328-32.
46. Bruns M, Hofmann C, Herrmann K, Haustein UF. Serum levels of soluble IL-2 receptor, soluble ICAM-1, TNF-alpha, interleukin-4 and interleukin-6 in scleroderma. J. Eur. Acad. Dermatol. Venereal. 1997; 8: 222-8.
47. White B. Immunopathogenesis of systemic sclerosis. Rheum. Dis. Clin. North Am. 1996; 22: 695-708.
48. Haustein UF, Anderegg U. Pathophysiology of scleroderma: An update. J. Eur. Acad. Dermatol. Venereal. 1998; 11: 1-8.
49. Denton CP, Abraham DJ. Transforming growth factor-beta and connective tissue growth factor: Key cytokines in scleroderma pathogenesis. Curr. Opin. Rheumatol. 2001; 13: 505-11.
50. Jelaska A, Korn JH. Role of apoptosis and transforming growth factor β1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum. 2000; 43: 2230-9.
51. Santiago B, Galindo M, Rivero M, Pablos JL. Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts. Arthritis Rheum. 2001; 44: 1667-76.
52. Ihn H, Yamane K, Kubo M, Tamaki K. Blockade of endogenous transforming growth factor beta signalling prevents upregulated collagen synthesis in scleroderma fibroblasts: Association with increased expression of transforming growth factor beta receptors. Arthritis Rheum. 2001; 44: 474-80.
53. Tan EM, Rodnan GP, Garcia I, Moral Y, Fritzler MJ, Peebles C. Diversity of antinuclear antibodies in progressive systemic sclerosis. Arthritis Rheum. 1980; 25: 617-25.
54. Ferri C, Bernini L, Cecchetti R, Latorraca A, Marotta G, Pasero G, Neri R, Bombardieri S. Cutaneous and serologic subsets of systemic sclerosis. J. Rheumatol. 1991; 18: 1826-32.
55. Meyer O. How useful are serum autoantibodies in the diagnosis and prognosis of systemic sclerosis. Clin. Rheumatol. 1998; 17: 179-80.
56. Davis K, Boros P, Keltz M, Unkeless JC, Fleischmajer R. Circulating Fc-γ receptor specific autoantibodies in localised and systemic scleroderma. J. Am. Acad. Dermatol. 1995; 33: 612-16.
57. Tan FK, Arnett FC, Antohi S, Saito S, Mirarchi A, Spiera H et al. Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. J. Immunol. 1999; 163: 1066-72.
58. Arnett FC, Tan FK, Uziel Y, Laxer RM, Krafchik BR, Antohi S, Bona C. Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with localised scleroderma. Arthritis Rheum. 1999; 42: 2656-9.
59. Spencer-Green G, Alter D, Welch HG. Test performance in systemic sclerosis: Anti-centromere and anti-Scl-70 antibodies. Am. J. Med. 1997; 103: 242-8.
60. Postlethwaite AE. Early immune events in scleroderma. Rheum. Dis. Clin. North Am. 1990; 16: 125-39.
61. Gruschwitz M, Van Den Driesch P, Kellner P, Hornstein OP, Sterry W. Expression of adhesion proteins involved in cell-cell and cell-matrix interactions in the skin of patients with progressive systemic sclerosis. J. Am. Acad. Dermatol. 1992; 27: 169-77.
62. Hasegawa M, Sato S, Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α) and MIP 1V) in patients with systemic sclerosis: MCP 1 and MIP 1α may be involved in the development of pulmonary fibrosis. Clin. Exp. Immunol. 1999; 117: 159-65.
63. Yurowsky VV, Wigley FM, Wise RA, White B. Skewing of the CD8+ T cell repertoire in the lungs of systemic sclerosis patients. Hum. Immunol. 1996; 48: 84-97.
64. Bianchi DW. Prenatal diagnosis by analysis of fetal cells in maternal blood. J. Pediatr. 1995; 127: 847-56.
65. Thomas MR, Williamson R, Craft I, Yazdani N, Rodeck CH. Y chromosome sequence DNA amplified from peripheral blood of women in early pregnancy. Lancet 1994; 343: 413-14.
66. Bianchi DW, Zickwolf GK, Weil GJ, Sylvester S, DeMaria MA. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. Proc. Natl Acad. Sci. USA 1996; 93: 705-8.
67. Nelson JL. Microchimerism and the pathogenesis of systemic sclerosis. Curr. Opin. Rheum. 1998; 10: 564-71.
68. Nelson JL. Maternal-fetal immunology and autoimmune disease: Is some autoimmune disease auto-alloimmune or alloautoimmune? Arthritis Rheum. 1996; 39: 191-4.
69. Furst DE, Clements PJ, Graze P, Gale R, Roberts N. A syndrome resembling progressive systemic sclerosis after bone marrow transplantation: A model for scleroderma. Arthritis Rheum. 1979; 22: 904-10.
70. Chosidow O, Bagot M, Vernant JP, Roujeau JC, Cordonnier C, Kuentz M, Wechsler J, Andre C, Touraine R, Revuz J. Sclerodermatous chronic graft versus host disease. J. Am. Acad. Dermatol. 1992; 26: 49-55.
71. Janin Mercier A, Devergie A, Van Cauwenberg D, Saurat JH, Bourges M, Lapiere M, Gluckman E. Immunohistologic and ultrastructural study of the sclerotic skin in chronic graft versus host disease in man. Am. J. Pathol. 1984; 115: 296-306.
72. Artlett CM, Cox LA, Jimenez SA. Detection of cellular microchimerism of male or female origin in systemic sclerosis patients by polymerase chain reaction analysis of HLA-Cw antigens. Arthritis Rheum. 2000; 43: 1062-7.
73. Johnson KL, Nelson JL, Furst DE, McSweeney PA, Roberts DJ, Zhen DK, Bianchi DW. Fetal cell microchimerism in tissue from multiple sites in women with systemic sclerosis. Arthritis Rheum. 2001; 44: 1848-54.
74. Nelson JL, Furst DE, Maloney S, Gooley T, Evans PC, Smith A, Bean MA, Ober C, Bianchi DW. Microchimerism and HLA-compatible relationships of pregnancy in SSc. Lancet 1998; 351: 559-62.
75. Nelson JL. Longterm persistence of fetal and maternal cells: Implications for systemic sclerosis and other autoimmune diseases. J. Rheumatol. 2000; 27: 2922-6.
76. Lo YMD, Lo ESF, Watson N, Noakes L, Sargent IL, Thilaganathan B, Wainscoat JS. Two way cell traffic between mother and fetus: Biologic and clinical implications. Blood 1996; 88: 4390-5.
77. Hall JM, Lingenfelter P, Adams SL, Lasser D, Hansen JA, Bean MA. Detection of maternal cells in human umbilical cord blood using fluorescence in situ hybridisation. Blood 1995; 86: 2829-32.
78. Artlett CM, Smith JB, Jimenez SA. Identification of fetal DNA and cells in skin lesions from women in systemic sclerosis. N. Engl. J. Med. 1998; 338: 1186-91.
79. Sayegh MH, Carpenter CB. Role of indirect allorecognition in allograft rejection. Intern. Rev. Immunol. 1996; 13: 221-9.
80. Pandey JP, LeRoy EC. Human cytomegalovirus and the vasculopathies of autoimmune disease (especially scleroderma), allograft rejector, and coronary restenosis. Arthritis Rheum. 1998; 41: 10-15.